|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results correspond with our analysis of the melanoma survival rates (SRs) from Human Protein Atlas and The Cancer Genome Atlas GDC (362 patients), where low <i>ER</i>β expression in melanoma correlate with a poor relapse-free survival, and no correlations were observed between SRs and <i>ER</i>α or <i>GPER</i> expression in melanoma.
|
31696058 |
2019 |
|
Pancreatic carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A frontline chemotherapy used for pancreatic cancer, i.e., gemcitabine (GEM) and a Hedgehog inhibitor (GDC 0449) has been used as the model combination to evaluate the encapsulation and pH-dependent release efficiency of these block copolymers.
|
30447521 |
2019 |
|
Malignant neoplasm of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
A frontline chemotherapy used for pancreatic cancer, i.e., gemcitabine (GEM) and a Hedgehog inhibitor (GDC 0449) has been used as the model combination to evaluate the encapsulation and pH-dependent release efficiency of these block copolymers.
|
30447521 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We used camcAPP, cBioPortal, CRN, and NIH NCI GDC Data Portal to data mine publicly available large prostate cancer datasets.
|
30616540 |
2019 |
|
Prostate carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We used camcAPP, cBioPortal, CRN, and NIH NCI GDC Data Portal to data mine publicly available large prostate cancer datasets.
|
30616540 |
2019 |
|
Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.
|
29457982 |
2018 |
|
Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
This work reveals new therapeutic targets for much needed podocyte-protective therapies and provides insights into the use of GDC-0879-like molecules for the treatment of progressive kidney diseases.
|
29249695 |
2018 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transcriptome and clinical HCC data were downloaded from the NIH-GDC repository.
|
30463528 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The legacy archive data of clinical information and genomic variations under the project TCGA Lung Adenocarcinoma were downloaded from the GDC Data Portal using R package TCGAbiolinks.
|
28503373 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The effects of GDC-0941 (a pan PI3K inhibitor), GDC-0980 (a dual PI3K/mTOR inhibitor) and GDC-0973 (a MEK inhibitor) alone and in combination were assessed in 3 NSCLC cell lines.PIK3CA was mutated in 5.17% of NSCLC patients.
|
27765909 |
2016 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
In addition, further investigations confirmed B cell lymphoma‑2 (Bcl‑2) as the downstream molecular mechanism of GDC‑0449 efficacy.
|
26676867 |
2016 |
|
Basal Cell Cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
GDC‑0449, a basal cell skin cancer target drug approved by the Food and Drugs Administration, is a smoothened (Smo)-specific antagonist.
|
26676867 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
GDC-0032 has increased potency in HNSCC cell lines harboringPIK3CA-activating aberrations.
|
26589432 |
2016 |
|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
GDC-0941-triggered WNT/beta-catenin pathway activation was observed in MDA-MB-231 and HCC1937 cells, which are TNBC cell lines showing aberrant WNT/beta-catenin activation, and not in SKBR3 and MCF7 cells.
|
25857298 |
2015 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
GDC-0941-triggered WNT/beta-catenin pathway activation was observed in MDA-MB-231 and HCC1937 cells, which are TNBC cell lines showing aberrant WNT/beta-catenin activation, and not in SKBR3 and MCF7 cells.
|
25857298 |
2015 |
|
Malignant Pleural Mesothelioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the combined use of ARQ 197/NVP-BEZ235 and ARQ 197/GDC-0980 is far more effective than the use of the drugs singly in suppressing MPM tumor growth and motility and therefore merit further translational studies.
|
25221930 |
2014 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Combination therapy with ABT-263 and GDC-0941 has novel therapeutic potential by specifically targeting aberrantly active, deregulated pathways in GBM, overcoming endogenous resistance to apoptosis.
|
24757258 |
2014 |
|
Chondrosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study.
|
24170610 |
2013 |
|
Sarcoma
|
0.010 |
Biomarker
|
group |
BEFREE |
GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study.
|
24170610 |
2013 |
|
HER2 gene amplification
|
0.010 |
Biomarker
|
disease |
BEFREE |
Oncogenic PIK3CA mutations and c-erbB2 gene amplification may represent biomarkers to identify patients harboring USC who may benefit most from the use of GDC-0980.
|
23891627 |
2013 |
|
Malignant neoplasm of soft tissue
|
0.010 |
Biomarker
|
group |
BEFREE |
GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study.
|
24170610 |
2013 |
|
Experimental Organism Basal Cell Carcinoma
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Thirty-three of 68 patients had advanced basal cell carcinoma (BCC), 8 had pancreatic cancer, 1 had medulloblastoma; 17 other types of cancer were also represented.GDC-0449 was generally well-tolerated.
|
21300762 |
2011 |
|
Metastatic basal cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GDC-0449, an orally active small molecule that targets the hedgehog pathway, appears to have antitumor activity in locally advanced or metastatic basal-cell carcinoma.
|
19726763 |
2009 |
|
Malignant neoplasm of breast
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
For newly-diagnosed breast cancer, the association between VWF and histology in the GDC Breast Cancer dataset in The Cancer Genome Atlas (TCGA) was evaluated.
|
31018945 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
These results correspond with our analysis of the melanoma survival rates (SRs) from Human Protein Atlas and The Cancer Genome Atlas GDC (362 patients), where low <i>ER</i>β expression in melanoma correlate with a poor relapse-free survival, and no correlations were observed between SRs and <i>ER</i>α or <i>GPER</i> expression in melanoma.
|
31696058 |
2019 |